Skip to main content
mental-health-gettyimages-1336438019

Where future-ready health meets wealth

 

 

Wealth is best enjoyed in good health

Financial planning ensures your wealth works for you, while a proactive approach to health helps you make the most of it.

By adopting positive lifestyle choices and building sustainable health habits, you can support your wellbeing and embrace a better quality of life – now and in the years ahead.

Man and woman running

Exclusive partnership between Manulife & Guardant Health

  • Commitment to your wellbeing and supporting you in early detection

  • First insurer across Singapore, Hong Kong and Philippines to offer a multi-cancer screening test

  • Exclusive opportunity to access the Multi-Cancer Detection (MCD)* test

Guardant Health, a global leader in blood-based cancer testing

As part of our commitment to your wellbeing and supporting you in early detection, we have partnered with Guardant Health - a global leader in blood-based cancer testing, with over a decade of experience1.

This exclusive partnership makes us the first insurer across Singapore, Hong Kong and the Philippines to offer a multi-cancer screening test.

Through this collaboration, you have the opportunity to access the Multi-Cancer Detection (MCD)* test when you purchase a qualifying plan today.

For more information please click on Learn more below.

Learn more
Promotional Cross-Selling Leaflet_R6 Extra 1080x0180

Here’s how you can access the Multi-Cancer Detection (MCD)* test

Start today and plan ahead with confidence – for both your health and your wealth.

1.  Speak with a Manulife Financial Representative on your financial needs

2. Purchase a suitable plan

3. Eligible customers receive a complimentary Multi-Cancer Detection (MCD) test*

Complimentary multi-cancer detection test worth up to SGD 2,000. Terms and conditions apply.

 

Learn more about Multi-Cancer Detection (MCD) test*

 

A doctor appointed by Guardant Health will first meet with you to explain the MCD test* and determine your eligibility for the test. A simple blood draw will be conducted after the doctor consultation, followed by nursing guidance to ensure post-draw comfort. Fasting is not required, but you are recommended to stay hydrated.  You may resume normal activities after the blood draw.

 

 

The Guardant Health’s MCD test* is not indicated for use in pregnant women and for people with a known diagnosis of cancer. Your clinical eligibility for Guardant Health’s MCD test* will be determined by the medical provider with whom you have scheduled your appointment.

 

 

Guardant Health is a leader in blood-based cancer tests for over a decade. The MCD test* by Guardant Health is backed by over 1 million oncology blood samples tested by Guardant Health1, a company that has demonstrated scientific rigour through over 600 peer reviewed publications1.

Guardant health’s MCD test* has received US FDA breakthrough device designation2.

 

 

The Guardant Health’s MCD test* does not diagnose cancer. Even with a positive signal, the individual should follow up with his/her physician for diagnostic follow-up to confirm the presence of specific cancer.

 

Ready to get started?

   

Want to find out more?

Let's arrange for a no-obligation chat with our financial consultant now!

       

Are you new to Manulife?

    

Select ID Type or policy number

   

Are you new to Manulife?

    

         

By submitting your personal details,

  • You acknowledge that you authorise and consent to Manulife (Singapore) Pte Ltd ("Manulife) (including employees and Representatives of Manulife) to collect, use, disclose and retain your personal data for the purpose of receiving notifications via SMS(es) and email(s) to service your request; and
  • You consent to Manulife to contact you (even though your telephone number may be already registered on the National Do Not Call Registry) for marketing purposes, and to provide you with marketing, advertising and promotional information, materials and/or documents relating to financial advisory services and products distributed by Manulife, if applicable.

The consent you provide is in addition to and does not supersede, vary or nullify any consent which you may have provided previously in respect of the above purposes, unless your previous consent has been withdrawn.

You also confirm that you are the user and/or subscriber of the telephone number and email address provided by you.

Important information

 

 

Guardant Health is a global leader in blood‑based cancer testing, with more than a decade of experience¹. The company has demonstrated strong scientific rigour, supported by over 600 peer‑reviewed publications¹, and pioneered blood‑based cancer testing with the first FDA‑approved liquid Comprehensive Genomic Profiling (CGP) test for all advanced solid tumours, alongside continued innovation reflected in more than 800 issued patents and patent applications3.

 

 

1. Data on file. Guardant Health, Inc. Sep, 2025. 

2. The US FDA Breakthrough Device designation referenced includes eight cancer types—bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic cancer.3

3. Guardant Health. FDA Grants Breakthrough Device Designation to Guardant Healthʼs Multi-Cancer Detection (MCD) Test. Published June 3, 2025. https://investors.guardanthealth.com/press-releases/press-releases/2025/FDA-Grants-Breakthrough-Device-Designation-to-Guardant-Healths-Shield-Multi-Cancer-Detection-MCD-Test/default.aspx

 

*Your clinical eligibility will be determined by the medical provider with whom you will schedule your appointment.

 

Better solutions for you

Insurance Savings Plans
Disciplined financial planning to make your dreams a reality.
 Learn more
Investment-linked Plans
Achieve more with both insurance and investment in one product.
 Learn more
Manulife Signature Plans
Grow and leave a legacy with our premium suite of solutions.
Learn more